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Data are lacking on whether lenalidomide maintenance therapy prolongs the time to
disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma.
Methods

Between April 2005 and July 2009, we randomly assigned 460 patients who were
younger than 71 years of age and had stable disease or a marginal, partial, or complete response 100 days after undergoing stem-cell transplantation to lenalidomide
or placebo, which was administered until disease progression. The starting dose of
lenalidomide was 10 mg per day (range, 5 to 15).
Results

The study-drug assignments were unblinded in 2009, when a planned interim analysis
showed a significantly longer time to disease progression in the lenalidomide group.
At unblinding, 20% of patients who received lenalidomide and 44% of patients who
received placebo had progressive disease or had died (P<0.001); of the remaining
128 patients who received placebo and who did not have progressive disease, 86
crossed over to lenalidomide. At a median follow-up of 34 months, 86 of 231 patients
who received lenalidomide (37%) and 132 of 229 patients who received placebo (58%)
had disease progression or had died. The median time to progression was 46 months
in the lenalidomide group and 27 months in the placebo group (P<0.001). A total of
35 patients who received lenalidomide (15%) and 53 patients who received placebo
(23%) died (P = 0.03). More grade 3 or 4 hematologic adverse events and grade 3 nonhematologic adverse events occurred in patients who received lenalidomide (P<0.001
for both comparisons). Second primary cancers occurred in 18 patients who received lenalidomide (8%) and 6 patients who received placebo (3%).
Conclusions

Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stemcell transplantation, was associated with more toxicity and second cancers but a
significantly longer time to disease progression and significantly improved overall
survival among patients with myeloma. (Funded by the National Cancer Institute;
ClinicalTrials.gov number, NCT00114101.)
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A

goal of therapy for multiple mye
loma, to induce complete remission and
prolong survival, is usually accomplished
with combination therapy.1,2 Autologous hematopoietic stem-cell transplantation is often used
after induction chemotherapy to improve the response or to consolidate complete remission.1,2
However, since most patients with multiple myeloma have disease recurrence or progression after
transplantation, maintenance therapies have been
used to prolong complete remission and prevent
relapse or progressive disease. Low-dose melphalan, interferon alfa, and glucocorticoids have been
used for maintenance after primary therapy, but
their long-term use is limited by toxicity and
modest efficacy.3-6
Five studies involving patients who had undergone autologous hematopoietic stem-cell transplantation showed that thalidomide maintenance
therapy improved progression-free survival, and
three of the five studies showed improved overall
survival.7-11 However, long-term thalidomide use is
limited by toxicity. A sixth study showed no benefit
with respect to progression-free survival or overall
survival, but 77% of the patients did not complete
maintenance therapy.12 Lenalidomide (Revlimid,
Celgene), an orally administered, immune-modulating drug, has several mechanisms of action
against multiple myeloma.13 It is an appealing
agent for long-term use because of its activity when
used alone at doses lower than induction doses
and its favorable toxicity profile.14 We designed a
phase 3, randomized, double-blind, placebocontrolled trial to determine whether lenalidomide therapy would prolong the time to disease
progression in patients with multiple myeloma
who had undergone induction therapy and a
single stem-cell transplantation. Secondary end
points included overall survival, the response
after transplantation, and the feasibility of longterm administration.

Me thods
Patients

Patients were eligible to participate in the trial if
they had multiple myeloma and were 18 to 70 years
of age. Other criteria were an Eastern Cooperative
Oncology Group performance status15 of 0 or 1 (on
a scale of 0 to 5, with 0 indicating that the patient
is fully active and 1 indicating that the patient is
restricted in physically strenuous activity but ambulatory and able to carry out work of a light or
n engl j med 366;19

sedentary nature), symptomatic disease requiring
treatment (Durie–Salmon stage ≥I) (for definitions
of the stages, see the Supplementary Appendix,
available with the full text of this article at NEJM
.org), and any induction regimen of 2 to 12 months’
duration. At most, two induction regimens (excluding dexamethasone alone) could have been
received.
Patients with stable disease or a marginal, partial, or complete response in the first 100 days
after stem-cell transplantation were eligible. The
minimum number of peripheral-blood stem cells
(CD34+ cells) for transplantation was 2×106 per
kilogram of body weight. Initially, the protocol
mandated peripheral-blood stem-cell mobilization
with cyclophosphamide and granulocyte colonystimulating factor within 42 days before transplantation, but the protocol was subsequently amended
to allow any mobilization and collection at any
time before transplantation. Adequate pulmonary,
cardiac, renal, and hepatic function was required,
and all patients were registered before transplantation. Serious coexisting conditions, including
uncontrolled diabetes, serious infections, and immune dysfunction, were exclusion criteria; pregnancy was also an exclusion criterion, and patients
participated in an informational program regarding the unknown teratogenic potential of lenalidomide.
After disease restaging, patients were randomly
assigned in a blinded manner to lenalidomide or
placebo between day 100 and day 110 after transplantation. All patients provided written informed
consent. The study was approved by the Cancer
and Leukemia Group B (CALGB), the Cancer
Therapy Evaluation Program of the National Cancer Institute (NCI), and the NCI central institutional review board.
Study Treatment and Oversight

The dosing schedule and adjustments, as well as
guidelines for anticoagulation, are described in the
Supplementary Appendix. The full protocol, along
with the statistical analysis plan, is available at
NEJM.org.
The NCI sponsored the study. Celgene provided
the lenalidomide and placebo to the NCI, which
in turn provided the study drugs to the investigators. Celgene had no involvement in the study design or conduct of the study or in the analysis or
reporting of the data. The study principal investigator and the members of the statistical center
vouch for the accuracy and completeness of the
nejm.org
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in this study as members of their respective cooperative groups and are responsible for the completeness of data reporting and the fidelity of
the study to the protocol.
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End Points and Definitions

The primary end point was time to progression,
defined as time to progressive disease or death
from any cause after transplantation. Response and
progression were defined initially according to the
criteria of the European Blood and Marrow Trans-

Table 1. Characteristics of the Patients.*
Lenalidomide
(N = 231)

Characteristic

Placebo
(N = 229)

Total
(N = 460)

Age — yr
Median

59

58

59

Range

29–71

40–71

29–71

121

129

250

>2.5 mg/liter

50 (22)

55 (24)

105 (23)

≤2.5 mg/liter

170 (74)

163 (71)

333 (72)

Data missing

11 (5)

11 (5)

22 (5)

35 (15)

28 (12)

63 (14)

Male sex — no.
β2-microglobulin at registration — no. (%)

Durie–Salmon stage at registration — no. (%)†
I
II

71 (31)

59 (26)

130 (28)

III

112 (48)

129 (56)

241 (52)

13 (6)

13 (6)

26 (6)

IgG kappa

70 (30)

76 (33)

146 (32)

IgG lambda

43 (19)

31 (14)

74 (16)

IgA kappa

21 (9)

20 (9)

41 (9)

IgA lambda

13 (6)

13 (6)

26 (6)

Data missing
M component — no. (%)
Serum

IgM kappa

2 (1)

1 (<1)

3 (1)

IgM lambda

0

1 (<1)

1 (<1)

Urine
Kappa light chain only
Lambda light chain only
Data missing
Nonsecretory myeloma — no. (%)

13 (6)

12 (5)

24 (5)

4 (2)

10 (4)

14 (3)

35 (15)

41 (18)

76 (17)

30 (13)

24 (10)

54 (12)

Serum calcium at registration — mg/dl
Median

9.1

9.1

9.1

Range

7.2–12.8

3.1–10.8

7.2–12.8

Serum albumin at registration — g/dl
Median

4.0

3.9

4.0

Range

1.4–4.9

2.9–5.0

1.4–5.0

Median

0.9

0.9

0.9

Range

0.4–1.9

0.5–2.2

0.4–2.2

Serum creatinine at registration — mg/dl
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Table 1. (Continued.)
Lenalidomide
(N = 231)

Placebo
(N = 229)

Total
(N = 460)

I

177 (77)

170 (74)

347 (75)

II

11 (5)

16 (7)

26 (6)

Characteristic
ISS stage at registration — no. (%)†

III
Data missing

4 (2)

3 (1)

7 (2)

39 (17)

40 (17)

79 (17)

98

91

189 (41)

Induction regimen — no.
Any use of bortezomib
Any use of lenalidomide

79

81

160 (35)

Any use of thalidomide

102

103

205 (45)

Bortezomib–lenalidomide‡

20

21

41 (9)

Bortezomib–thalidomide‡

33

27

60 (13)

Bortezomib without lenalidomide or thalidomide

43

40

83 (18)

Bortezomib with glucocorticoids, without lenalidomide
or thalidomide

40

32

72 (16)

Bortezomib with lenalidomide and thalidomide
Lenalidomide without bortezomib

2

3

5 (1)

57

57

114 (25)

Thalidomide without bortezomib

67

72

139 (30)

Lenalidomide–glucocorticoids without bortezomib

56

56

112 (24)

Thalidomide–glucocorticoids without bortezomib

65

72

137 (30)

Other induction regimen without bortezomib, lenalidomide,
or thalidomide

15

13

28 (6)

0

1

   1 (<1)

Other induction regimen not determined
Response to autologous HSCT at day 100 — no. (%)
Complete response
Partial response

67 (29)

79 (34)

146 (32)

115 (50)

109 (48)

224 (49)

Marginal response

11 (5)

5 (2)

16 (3)

Stable disease

38 (16)

32 (14)

70 (15)

Progressive disease

0

3 (1)

3 (1)

Data missing

0

1 (<1)

   1 (<1)

3.3

3.3

Mean time from autologous HSCT to randomization — mo

* The first patient was enrolled in April 2005, and the study was closed to enrollment in July 2009. To convert the values
for serum β2-microglobulin to nanomoles per liter, multiply by 84.75. To convert the values for calcium to millimoles
per liter, multiply by 0.250. To convert the values for creatinine to micromoles per liter, multiply by 88.4. There were no
significant differences (P<0.05) between the lenalidomide and placebo groups with respect to baseline characteristics.
There was an overlap in the induction regimens, so percentages may sum to more than 100%. HSCT denotes hematopoietic stem-cell transplantation, and ISS International Staging System.
† Higher stages indicate more severe disease. The staging criteria are defined in the Supplementary Appendix.
‡ Patients who received this regimen received at least these two drugs.

plant Group16; these definitions were subsequently changed to be consistent with the criteria of the
International Myeloma Working Group17 (see the
Supplementary Appendix for details).

n engl j med 366;19
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the lenalidomide group than in the placebo group.
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The study was designed to have 90% power, with
the use of the log-rank test at a one-sided significance level of 0.05, to detect a hazard ratio of
1.4, assuming proportional hazards and an exponential time-to-event distribution. Under the assumed framework, 309 events were expected. The
expected dropout rate before randomization was
15%. Of 568 patients registered from 47 centers,
460 were randomly assigned to a study group with
the use of a permuted-block design, stratified according to three baseline factors: normal or elevated serum β2-microglobulin level at registration
(≤2.5 mg per liter vs. >2.5 mg per liter [≤211.9 nmol
per liter vs. >211.9 nmol per liter]), prior use or
nonuse of thalidomide during induction therapy;
and prior use or nonuse of lenalidomide during
induction therapy. The time-to-progression end
point was monitored with the use of a groupsequential design for superiority and futility. Interim analyses of time to progression, overall
survival, and adverse events were presented to the
data and safety monitoring board of the CALGB
twice a year when more than 20% of the expected
events had occurred.
The data were released to the study team on
December 17, 2009, after the third review because
statistical evidence favored the lenalidomide group;
this finding was observed after the first report
to the data and safety monitoring board in June
2009. The analyses were based on the intentionto-treat principle and included follow-up data
submitted on or before December 17, 2009 (the
unblinding date) or follow-up data submitted as
of October 31, 2011 (for evaluation of long-term
outcomes). To assess the occurrence of second
primary cancers reported after randomization,
the nonprotocol end point of event-free survival,
defined as time to first event (second primary cancer, progressive disease, or death) was considered.
Starting in December 2010, the statistical center
sent three sets of queries to all participating sites,
and specific questionnaires were sent to all centers
regarding cancer screening and second primary
cancers. The last screening was conducted on January 1, 2012, and no new cases had been reported
since the October 31, 2011, data analysis.
Survival functions were estimated with the use
of the Kaplan–Meier method.18 Discrepancies between survival functions were estimated with the
use of the hazard ratios from a Cox model,19 under the implicit assumption of proportional hazards. To assess the predictive value of baseline co1774
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variables, a two-way multiplicative Cox model19
was used. To assess cause-specific risk (progression, death, and second primary cancers), the cumulative incidence curves were estimated with the
use of the Kaplan–Meier method20 and compared
with the use of the log-rank test proposed by
Gray.21 All analyses were right-censored since not
all events had occurred at the time of the analysis,
and as specified by the protocol, the date of transplantation was used as the reference date. The
differences between proportions of patients with
adverse events were tested with the use of Fisher’s
exact test22 and estimated with the use of a conditional maximum-likelihood estimator of the odds
ratio.22 Asymptotic P values of less than 10−3 were
denoted as P<0.001. The analyses were conducted
with R Statistical Environment software, version
2.14.1 (R Development Core Team 2011) along with
survival and cmprsk extension packages. A detailed
description of statistical considerations, including
methods of design and analysis, is available in the
Supplementary Appendix.

R e sult s
Characteristics of the Patients

Of the 568 patients enrolled in the study, 460 were
randomly assigned to a study group: 231 to the
lenalidomide group and 229 to the placebo group.
(Fig. S1a and S1b in the Supplementary Appendix
provide detailed information on the numbers of
patients who were enrolled, assigned to a study
group, and included in follow-up.) Age, sex, disease stage, and serum β2-microglobulin level at
registration were evenly distributed in the two
groups (Table 1). Cytogenetic analysis was not
required. The majority of patients received induction therapy with a regimen containing lenalidomide, thalidomide, or bortezomib, or a combination of the three (Table 1).
Time to Progression and Overall Survival

The study was unblinded on December 17, 2009,
after a median follow-up of 18 months, when 47 of
the 231 patients in the lenalidomide group (20%)
as compared with 101 of the 229 patients in the
placebo group (44%) had progressive disease or
had died (P<0.001). The hazard ratio for the risk
of progression or death from any cause was 0.37
(95% confidence interval [CI], 0.26 to 0.53), indicating a 63% reduction in the risk of progressive
disease or death among patients in the lenalidonejm.org
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Probability of Overall Survival

Probability of Progression-free Survival

mide group. The median time to progression was
A
39 months among patients in the lenalidomide
1.0
group and 21 months among patients in the plaTwo-sided P<0.001
cebo group (P<0.001) (Fig. S2a in the Supplementary Appendix). As of December 17, 2009, a total of
0.8
13 of the 231 patients in the lenalidomide group
(6%) and 24 of the 229 patients in the placebo
0.6
group (10%) had died (hazard ratio, 0.52; 95%
CI, 0.26 to 1.02; two-sided P = 0.05). The median
Lenalidomide
overall survival had not been reached for either
0.4
group (Fig. S2b in the Supplementary Appendix).
The primary end point (time to progression) was
0.2
met, and the study was unblinded so that paPlacebo
tients in the placebo group could cross over to
lenalidomide therapy. Of 128 eligible patients
0.0
without disease progression in the placebo group,
0
10
20
30
40
50
60
70
86 received lenalidomide therapy.
Months since Autologous HSCT
The median follow-up as of October 31, 2011,
B
was 34 months. Eighty-six of the 231 patients in
1.0
the lenalidomide group (37%) as compared with
132 of the 229 patients in the placebo group (58%)
had disease progression or had died (hazard ratio,
0.8
Lenalidomide
0.48; 95% CI, 0.36 to 0.63). The median time to
progression was 46 months in the lenalidomide
0.6
Placebo
group and 27 months in the placebo group
(P<0.001) (Fig. 1A). The 3-year rate of freedom
from progression or death was 66% (95% CI,
0.4
59 to 73) among patients in the lenalidomide
Two-sided P=0.03
group and 39% (95% CI, 33 to 48) among patients
0.2
in the placebo group. A total of 35 patients who
received lenalidomide (15%) and 53 patients who
received placebo (23%) died (two-sided P = 0.03).
0.0
Thus, 85% of the patients in the lenalidomide
0
10
20
30
40
50
60
70
group and 77% of the patients in the placebo
Months since Autologous HSCT
group were alive at the time of the analysis. The
Figure 1. Kaplan–Meier Estimates of Progression-free and Overall Survival.
rate of overall survival at 3 years was 88% (95% CI,
HSCT denotes hematopoietic stem-cell transplantation.
84 to 93) among patients in the lenalidomide
group and 80% (95% CI, 74 to 86) among patients in the placebo group (hazard ratio, 0.62;
with lenalidomide (yes vs. no). Figure 2A shows a
95% CI, 0.40 to 0.95) (Fig. 1B).
forest plot comparing the relative influence of stratTime to Progression According to
ification factors on time to progression. There was
Stratification at Randomization
a trend toward a greater difference in time to proTime to progression according to the β2-micro gression with lenalidomide than with placebo for
globulin level at registration (normal vs. elevated) status with respect to lenalidomide induction theris shown in Figure S2c in the Supplementary Ap- apy (P = 0.06 for interaction).
pendix. Figure S2d in the Supplementary Appendix
shows time to progression according to status with Time to Progression According to Response
respect to prior induction therapy with thalidomide at Randomization
(yes vs. no), and Figure S2e in the Supplementary Table 1 shows the responses of the patients to auAppendix shows time to progression according tologous hematopoietic stem-cell transplantation
to status with respect to prior induction therapy at randomization. The time to progression accordn engl j med 366;19
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A Time to Progression
Subgroup

Hazard Ratio (95% CI)

Lenalidomide induction
Yes
No
Thalidomide induction
Yes
No
Elevated β2-microglobulin level
Yes
No
Complete response at randomization
Yes
No

P Value for
Interaction
0.06

1.10 (0.58 to 1.7)
0.57 (0.25 to 0.89)
0.36
0.57 (0.17 to 0.98)
0.86 (0.49 to 1.2)
0.76
0.67 (0.17 to 1.2)
0.77 (0.44 to 1.1)
0.38
0.53 (−0.001 to 1.1)
0.86 (0.53 to 1.2)
−2

−1

0

Placebo Better

1

2

Lenalidomide Better

B Overall Survival
Subgroup

Hazard Ratio (95% CI)

Lenalidomide induction
Yes
No
Thalidomide induction
Yes
No
Elevated β2-microglobulin level
Yes
No
Complete response at randomization
Yes
No

P Value for
Interaction
0.03

1.40 (0.43 to 2.4)
0.18 (−0.32 to 0.67)
0.05
0.01 (−0.62 to 0.64)
0.89 (0.29 to 1.5)
0.56
0.37 (−0.39 to 1.1)
0.58 (0.06 to 1.1)
0.64
0.25 (−0.67 to 1.2)
0.53 (0.05 to 1.0)
−2

−1

Placebo Better

0

1

2

Lenalidomide Better

Figure 2. Forest Plot of Time to Progression and Overall Survival.
Hazard ratios from subgroup analyses of time to disease progression and overall survival in the randomized population are
shown (on a natural-log scale). The radii of the circles are proportional to the inverse of the square of the standard error.

ing to the response at randomization is shown for
the analysis of data at the time of unblinding and
for the later analysis in Figures S2f and S2g in the
Supplementary Appendix, respectively. Figure 2A
shows a forest plot comparing the relative influence
of responses to induction therapy and transplantation and random assignment to lenalidomide or
placebo on the time to progression in the two
study groups. We cannot conclude that there was
an interaction between remission status at randomization and maintenance therapy with respect to
time to progression (P = 0.38). However, lenalidomide maintenance therapy appeared to increase
the time to progression in patients who did not
have complete remission at day 100 after transplantation.
1776
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Overall Survival According to Stratification
at Randomization

Figure S2h in the Supplementary Appendix shows
overall survival according to the β2-microglobulin
level at randomization (normal vs. elevated). Figure S2i in the Supplementary Appendix shows
overall survival according to status with respect
to prior induction therapy with thalidomide (yes
vs. no), and Figure S2j in the Supplementary Appendix shows overall survival according to status
with respect to prior induction therapy with lenalidomide (yes vs. no). Overall survival did not
differ significantly between the lenalidomide
and placebo groups when they were stratified according to the β2-microglobulin level and status
with respect to prior thalidomide exposure. Fignejm.org
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Table 2. Hematologic Adverse Events from Randomization to February 2012.*
Event

Lenalidomide (N = 231)
Grade 3

Grade 4

Placebo (N = 229)
Grade 3

P Value

Grade 4

number of patients (percent)
Neutropenia

74 (32)

30 (13)

27 (12)

7 (3)

<0.001

Thrombocytopenia

21 (9)

11 (5)

3 (1)

8 (3)

0.001

Lymphopenia

15 (6)

1 (<1)

3 (1)

1 (<1)

0.01

9 (4)

2 (1)

1 (<1)

0

0.006

Anemia
Leukocytopenia

24 (10)

3 (1)

7 (3)

Any event

74 (32)

36 (16)

27 (12)

1 (<1)
12 (5)

0.001
<0.001

* Hematologic adverse events that occurred five or more times in either study group as of February 2012 are listed. For
patients with multiple adverse events, the event with the highest grade is listed. There were no grade 5 hematologic
adverse events in either group. Adverse events were graded according to the National Cancer Institute Common Termi
nology Criteria for Adverse Events, version 3.0. As of December 2009, grade 3, 4, or 5 neutropenia had occurred in 64
patients (28%), 24 patients (10%), and no patients in the lenalidomide group and in 14 patients (6%), 4 patients (2%),
and no patients in the placebo group, respectively. Grade 3, 4, or 5 thrombocytopenia had occurred in 17 patients (7%),
10 patients (4%), and no patients in the lenalidomide group and in 1 patient (<1%), 7 patients (3%), and no patients in
the placebo group, respectively. Grade 3, 4, or 5 lymphopenia had occurred in 11 patients (5%), 5 patients (2%), and no
patients in the lenalidomide group and in 1 patient (<1%), 1 patient (<1%), and no patients in the placebo group, respectively. Grade 3, 4, or 5 anemia had occurred in 8 patients (3%), 1 patient (<1%), and no patients in the lenalidomide group and in 1 patient (<1%), no patients, and no patients in the placebo group, respectively.

ure 2B shows a forest plot comparing the relative
influence of responses to induction therapy and
transplantation and random assignment to lenalidomide or placebo on overall survival. The
data provide evidence that induction therapy with
lenalidomide was associated with improved overall survival in the group that received lenalidomide maintenance therapy as compared with the
placebo group (P = 0.03).
Adverse Events and Second Primary Cancers

Adverse events after randomization (up to February 2012) are summarized in Table 2 and in Tables
S1 and S2 in the Supplementary Appendix. More
grade 3 or 4 hematologic adverse events occurred in
patients in the lenalidomide group than in the placebo group (P<0.001); in particular, more patients
in the lenalidomide group had grade 3 or 4 neutropenia. There were no grade 5 hematologic adverse events. There were more grade 3 nonhematologic adverse events in the lenalidomide group
than in the placebo group (P<0.001); there were no
significant differences between the groups with respect to the numbers of grade 4 and grade 5 nonhematologic adverse events.
A total of 23 of 231 patients in the lenalidomide group discontinued therapy because of
adverse events. Two of 143 patients in the plan engl j med 366;19

cebo group who did not cross over to lenalidomide discontinued therapy because of adverse
events, and 5 of 86 patients in the placebo group
who crossed over to lenalidomide discontinued
therapy because of adverse events (see Fig. S1a
and S1b in the Supplementary Appendix).
After randomization, 8 new hematologic cancers and 10 solid-tumor cancers (excluding nonmelanoma skin cancers) were diagnosed among
the 231 patients in the lenalidomide group (3.5%
and 4.3%, respectively). The corresponding numbers of new hematologic and solid-tumor cancers
among the 229 patients in the placebo group were
1 (0.4%) and 5 (2.2%) (Table 3). The median time
to the diagnosis of a hematologic cancer after randomization was 28 months (range, 12 to 46) in
patients in the lenalidomide group, and the 1 hematologic cancer that occurred in a patient in the
placebo group was diagnosed at 30 months. The
median time to the diagnosis of a solid-tumor
cancer after randomization was 15 months (range,
3 to 51) in the lenalidomide group and 21 months
(range, 6 to 34) in the placebo group. Four of 10
patients with solid tumors restarted lenalidomide
after surgery for their second primary cancer. One
case of a second primary cancer (melanoma) was
reported in a patient in the placebo group after
crossover to lenalidomide.
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Table 3. Second Primary Cancers from Randomization to February 2012.
Lenalidomide
(N = 231)

Second Cancer

Placebo
(N = 229)

number of patients
Hematologic cancers*
Acute lymphoblastic leukemia

1

0

Acute myeloid leukemia

5

0

Hodgkin’s lymphoma

1

0

Myelodysplastic syndrome

1

0

Non-Hodgkin’s lymphoma

0

1

Total

8

1

Breast cancer

3

0

Carcinoid tumor

0

1

Central nervous system cancer

1

0

Gastrointestinal cancer

2

1

Gynecologic cancer

1

1

Malignant melanoma

1

2

Prostate cancer

1

0

1

0

10

5

Solid-tumor cancers

Thyroid cancer
Total
Basal-cell carcinoma

2

1

Squamous-cell carcinoma

2

2

* Four of the eight patients with a hematologic cancer in the lenalidomide
group received induction therapy with an anthracycline. One solid-tumor cancer occurred in a patient with breast cancer in the lenalidomide group. This
patient had primary breast cancer 26 years before presentation with metastatic
disease. It is not known whether this breast cancer was a new primary cancer
or a recurrence of the original breast cancer. Two cases of solid tumors (one
in the lenalidomide group and one in the placebo group) occurred after disease
progression. These cases were not included in the analysis of second primary
cancers, since they occurred after disease progression and then further therapy.

Event-Free Survival and Cumulative Incidence
of Disease Progression, Second Primary
Cancers, and Deaths

Event-free survival was a post hoc end point to assess the influence of second primary cancers on
the observed time to progression and overall survival. Cases of nonmelanoma skin cancer (all local, without distant spread) were not classified as
second primary cancers in the analysis. As of October 31, 2011, a total of 92 of the 231 patients in
the lenalidomide group (40%) as compared with
133 of the 229 patients in the placebo group (58%)
had progressive disease, had died, or had received
a diagnosis of a second primary cancer (P<0.001).
The estimated hazard ratio was 0.53 (95% CI, 0.41
to 0.69), indicating a 47% reduction in risk among
1778
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patients in the lenalidomide group. The median
event-free survival was 43 months among patients
in the lenalidomide group and 27 months among
patients in the placebo group (Fig. S2k in the Supplementary Appendix). To further assess the causespecific risk profiles, we estimated the cumulative
incidence risks of a second primary cancer, disease
progression, and death, stratified according to
group. The cumulative incidence of a second primary cancer was higher among patients in the lenalidomide group than among patients in the placebo group (P = 0.008). The cumulative incidence of
progressive disease and the cumulative incidence
of death were higher among patients in the placebo
group than among patients in the lenalidomide
group (P<0.001 and P = 0.002, respectively) (Fig. 3).

Discussion
Although a cure for multiple myeloma is still not
possible in most patients, maintenance of a prolonged progression-free interval with minimal toxicity is an important goal in the management of
this disease. The median overall survival among
patients who required therapy before 1996 was approximately 3 years.23 In the era of new agents and
autologous hematopoietic stem-cell transplantation, the median overall survival after transplantation is close to 8 years.23,24 In this study, 85% of
patients in the lenalidomide group and 77% of patients in the placebo group were alive at a median
follow-up of nearly 3 years.
Several strategies have been implemented to
improve the response to primary therapy since it
correlates with the outcome.25-27 Patients with
multiple myeloma who have complete remission
after primary therapy appear to have a longer time
to progression, resulting in prolonged overall
survival, although patients with a very good partial response (>90% reduction in myeloma protein) may have excellent outcomes.25 Maintenance
of disease control without clinically significant
progression and dose-limiting toxic effects, as
well as tolerability for the patient, may also translate into prolonged overall survival. Lenalidomide
maintenance may increase the time to progression in patients who do not have complete remission after induction therapy and transplantation,
thus generating outcomes similar to those for
patients with complete remission. Although the
response criteria of the International Myeloma
Working Group were not used for all patients in
nejm.org
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1.0

Disease progression
Death
Second primary cancer

0.8

Cumulative Incidence

this study, the results are consistent with those
of previous studies with respect to response and
outcome.
Diagnostic cytogenetic abnormalities in multiple myeloma have been associated with the outcome.28 Cytogenetic analysis was not required for
enrollment in this study; however, a review of available data is ongoing. We expect this information
to better define populations that would benefit
most from lenalidomide maintenance therapy. Patients with disease progression before day 100 after autologous hematopoietic stem-cell transplantation (4% of the patients who were registered in
our study) were not eligible to undergo randomization. We cannot conclusively say whether induction
regimens with multiple drugs could overcome progressive disease and whether this group of patients
would benefit from maintenance therapy after
transplantation.
Consolidation therapy after induction therapy
and transplantation is one strategy that improves
outcomes. Consolidation appears to be most effective in inducing complete remission in patients
with residual disease.29,30 Consolidation therapy
is more intensive than maintenance therapy, often
with toxic effects. In this study, lenalidomide
maintenance as a form of prolonged therapy, as
compared with placebo, prolonged the time to
progression and increased overall survival.
Despite its demonstrated efficacy, thalidomide
maintenance therapy has been limited by neurotoxicity, with up to 75% of patients discontinuing
maintenance therapy.7-12 Other studies have shown
that lenalidomide and bortezomib used as maintenance therapy are better tolerated, with clinically
significant efficacy for long-term maintenance after autologous hematopoietic stem-cell transplantation.31,32 In this issue of the Journal, Attal et al.33
also report a significantly prolonged time to disease progression with lenalidomide maintenance
therapy after autologous hematopoietic stem-cell
transplantation. A related article by Palumbo et
al.34 describes a significantly prolonged time to
disease progression with lenalidomide maintenance therapy after the use of low-dose induction
therapy. These three studies show the usefulness
of lenalidomide maintenance therapy for prolonging the time to disease progression in both patients who have undergone stem-cell transplantation and those who have not. The study reported
by Attal et al.33 did not show an overall survival
benefit, a finding that could be due to differ-

0.6
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Placebo
0.2
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Lenalidomide
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Figure 3. Cumulative Incidence of Second Primary Cancers, Disease
Progression, and Death in the Lenalidomide and Placebo Groups after
Randomization.
The cumulative incidence risk of second primary cancers was greater in the
lenalidomide group than in the placebo group (P = 0.0008). The cumulative
incidence risks of progressive disease and death were greater in the placebo
group (P<0.001 for progression and P = 0.002 for death). All P values are
two-sided.

ences in induction (use or nonuse of lenalidomide-based induction therapy) and consolidation
(use or nonuse of more alkylator-based chemotherapy) before transplantation, the use of lenalidomide consolidation therapy in both groups after
transplantation, the use of two transplantations
in some patients, and the discontinuation of maintenance therapy.33 Longer follow-up and additional studies may clarify the different findings.
A major concern during maintenance therapy is
toxicity that limits long-term use and the ability
to receive future treatment after disease progression or that results in life-threatening disorders.
Acute myeloid leukemia or the myelodysplastic
syndrome has been reported in patients with multiple myeloma who did not undergo transplantation and were treated with melphalan.35,36 An
observational bias is unlikely to explain these findings because of the rapid development of acute
myeloid leukemia and, to a lesser extent, the myelodysplastic syndrome. A recent report by the
Swedish Cancer Registry described an increased
incidence of these disorders in patients with mulnejm.org
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tiple myeloma and monoclonal gammopathy of
undetermined significance (MGUS).37 The finding that acute myeloid leukemia or the myelodysplastic syndrome occurs in untreated patients
with MGUS suggests that these plasma-cell disorders are associated with a hematopoietic stemcell or microenvironmental defect in addition to
an effect of chemotherapy exposure. Multiple
myeloma is also associated with solid-tumor cancers.38 In this study, the increase in second primary solid-tumor cancers in the lenalidomide
group was not associated with a specific tumor
type, and the cause was uncertain. Close monitoring of blood counts, as indicated by the study
guidelines, and standard screening for cancers
are recommended.

of

m e dic i n e

In conclusion, this study suggests that lenalidomide maintenance therapy until disease progression is feasible for prolonged administration. The
increase in time to progression led to early study
unblinding, and despite the crossover, benefits
with respect to progression and overall survival
were seen in patients receiving lenalidomide maintenance therapy, especially those who had received
lenalidomide-based induction therapy. It remains
to be determined whether the incorporation of
other new agents with lenalidomide will further
increase the time to disease progression and
overall survival.
Supported by the National Cancer Institute.
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.
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